Wall Street brokerages predict that Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) will report ($0.10) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Brainstorm Cell Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.03) and the lowest estimate coming in at ($0.18). Brainstorm Cell Therapeutics posted earnings per share of $0.02 in the same quarter last year, which suggests a negative year over year growth rate of 600%. The firm is scheduled to report its next earnings results on Thursday, March 14th.
On average, analysts expect that Brainstorm Cell Therapeutics will report full year earnings of ($0.53) per share for the current fiscal year, with EPS estimates ranging from ($0.61) to ($0.47). For the next year, analysts anticipate that the firm will post earnings of ($0.30) per share, with EPS estimates ranging from ($0.69) to ($0.10). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Brainstorm Cell Therapeutics.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings data on Monday, October 29th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.05).
A number of equities research analysts have weighed in on the company. Maxim Group restated a “buy” rating and set a $9.00 price target on shares of Brainstorm Cell Therapeutics in a research report on Monday, December 17th. HC Wainwright set a $11.00 price target on Brainstorm Cell Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 18th. Finally, Dawson James restated a “buy” rating on shares of Brainstorm Cell Therapeutics in a research report on Tuesday, December 18th.
NASDAQ BCLI traded down $0.08 during trading hours on Monday, reaching $3.37. 558,223 shares of the stock traded hands, compared to its average volume of 114,440. Brainstorm Cell Therapeutics has a 1 year low of $2.88 and a 1 year high of $5.35. The company has a market capitalization of $69.99 million, a price-to-earnings ratio of -12.96 and a beta of 1.41.
An institutional investor recently raised its position in Brainstorm Cell Therapeutics stock. Renaissance Technologies LLC raised its position in shares of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) by 16.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 133,900 shares of the biotechnology company’s stock after purchasing an additional 18,500 shares during the period. Renaissance Technologies LLC owned approximately 0.65% of Brainstorm Cell Therapeutics worth $511,000 at the end of the most recent reporting period. 11.44% of the stock is owned by hedge funds and other institutional investors.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Featured Article: What are different types of coverage ratios?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.